newsfilter
← Latest News
GlobeNewswire·

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexin Agonist Program: Cleared IND and initiated Phase